TPST · Tempest Therapeutics, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| R&D | $12.61M | $28.48M | $17.50M | $22.53M | $17.17M | $20.37M |
| SG&A | $13.97M | $13.55M | $11.66M | $12.11M | $9.82M | $15.60M |
| Total Operating Expenses | - | - | - | - | - | - |
| D&A | $266.0K | $389.0K | $381.0K | $638.0K | $374.0K | $152.0K |
| Operating Income | ($26.57M) | ($42.03M) | ($29.16M) | ($34.64M) | ($26.99M) | ($35.97M) |
| Interest Expense | $207.0K | $1.32M | $1.45M | $1.62M | $0 | - |
| Income Tax | $0 | $0 | $0 | $0 | $0 | - |
| Net Income | ($26.26M) | ($41.84M) | ($29.49M) | ($35.71M) | ($28.30M) | ($36.41M) |
| EPS - Basic | ($6.33) | ($19.50) | ($24.83) | ($40.17) | ($533.39) | - |
| EPS - Diluted | ($6.33) | ($19.50) | ($24.83) | ($40.17) | ($533.39) | - |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $7.71M | $30.27M | $39.23M | $31.23M | $51.83M | $38.17M |
| Accounts Receivable | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - |
| Accounts Payable | $1.04M | $2.45M | $845.0K | $1.11M | $991.0K | $1.49M |
| Current Assets | $8.27M | $31.47M | $40.36M | $32.95M | $68.96M | $40.90M |
| Total Assets | $16.93M | $41.49M | $51.60M | $46.09M | $73.24M | $43.41M |
| Current Liabilities | $3.31M | $14.22M | $9.41M | $7.28M | $20.03M | $7.99M |
| Long-term Debt | - | $0 | $6.26M | $10.37M | $15.07M | $61.0K |
| Total Liabilities | $10.26M | $22.36M | $24.84M | $27.98M | $37.12M | $9.68M |
| Stockholders' Equity | $6.67M | $19.13M | $26.77M | $18.11M | $36.12M | $33.06M |
| Retained Earnings | ($233.37M) | ($207.11M) | ($165.26M) | ($135.77M) | ($100.06M) | ($245.06M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | ($26.82M) | ($33.03M) | ($27.36M) | ($31.07M) | ($25.96M) | ($30.43M) |
| Investing Cash Flow | $0 | ($435.0K) | ($170.0K) | ($562.0K) | ($97.0K) | ($26.0K) |
| Financing Cash Flow | $4.26M | $24.50M | $35.60M | $11.40M | $59.06M | $5.39M |
| CapEx | $0 | $435.0K | $170.0K | $562.0K | $135.0K | $26.0K |
| Free Cash Flow | ($26.82M) | ($33.46M) | ($27.53M) | ($31.63M) | ($26.09M) | ($30.46M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - |
| FCF / Net income | 1.02 | 0.80 | 0.93 | 0.89 | 0.92 | 0.84 |
| R&D / Revenue | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -155.1% | -100.9% | -57.1% | -77.5% | -38.6% | -83.9% |
| Return on equity | -393.9% | -218.8% | -110.2% | -197.2% | -78.4% | -110.1% |
| Return on invested capital | - | -173.6% | -69.7% | -96.1% | -41.6% | - |
| Liquidity | ||||||
| Current ratio | 2.50 | 2.21 | 4.29 | 4.53 | 3.44 | 5.12 |
| Quick ratio | 2.50 | 2.21 | 4.29 | 4.53 | 3.44 | 5.12 |
| Cash ratio | 2.33 | 2.13 | 4.17 | 4.29 | 2.59 | 4.78 |
| Leverage | ||||||
| Debt / Equity | - | 0.00 | 0.23 | 0.57 | 0.42 | 0.00 |
| Debt / Assets | - | 0.00 | 0.12 | 0.23 | 0.21 | 0.00 |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | -128.4x | -31.9x | -20.1x | -21.4x | - | - |
| Equity multiplier | 2.54 | 2.17 | 1.93 | 2.54 | 2.03 | 1.31 |
| Liabilities / Assets | 0.61 | 0.54 | 0.48 | 0.61 | 0.51 | 0.22 |
| Efficiency | ||||||
| Asset turnover | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 1.8x | 15.8x | 32.9x | 9.5x | 0.9x | - |
| P / S | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - |
| Operating income growth (YoY) | 36.8% | -44.1% | 15.8% | -28.4% | 25.0% | 20.8% |
| Net income growth (YoY) | 37.2% | -41.9% | 17.4% | -26.2% | 22.3% | 18.3% |
| EPS growth (YoY) | 67.5% | 21.5% | 38.2% | 92.5% | - | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 19.8% | -21.6% | 13.0% | -21.2% | 14.3% | 26.8% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | -65.1% | -28.5% | 47.8% | -49.9% | 9.3% | -43.5% |
Stability scores
Piotroski F-score
FY 2025 · 9-point quality
2/9
Weak
- ✗Net income positive
- ✗Operating cash flow positive
- ✗ROA improved YoY
- ✗Cash flow > net income
- -Long-term debt decreased
- ✓Current ratio improved
- ✓No share dilution
- -Gross margin improved
- -Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Tempest Therapeutics against the 5 most active filers in the same SIC group.